1 |
Cacoub P, Comarmond C, Vieira M, Régnier P, Saadoun D. HCV-related lymphoproliferative disorders in the direct-acting antiviral era: From mixed cryoglobulinaemia to B-cell lymphoma. J Hepatol 2021:S0168-8278(21)02084-5. [PMID: 34600000 DOI: 10.1016/j.jhep.2021.09.023] [Reference Citation Analysis]
|
2 |
Sakai H, Miwa T, Ikoma Y, Hanai T, Nakamura N, Imai K, Kitagawa J, Shirakami Y, Kanemura N, Suetsugu A, Takai K, Shiraki M, Shimizu M. Development of diffuse large B-cell lymphoma after sofosbuvir-ledipasvir treatment for chronic hepatitis C: A case report and literature review. Mol Clin Oncol 2020;13:1. [PMID: 32754315 DOI: 10.3892/mco.2020.2071] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
3 |
Wang W, Lo Re V 3rd, Guo Y, Xiao H, Brown J, Park H. Impact of hepatitis C virus treatment on the risk of non-hepatic cancers among hepatitis C virus-infected patients in the US. Aliment Pharmacol Ther 2020;52:1592-602. [PMID: 32931606 DOI: 10.1111/apt.16081] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
4 |
Butt AA, Yan P; ERCHIVES study team. Natural history of hepatitis C virus infection in a large national seroconversion cohort in the direct-acting antiviral agent era: Results from ERCHIVES. J Viral Hepat 2021;28:916-24. [PMID: 33763947 DOI: 10.1111/jvh.13507] [Reference Citation Analysis]
|